Abliva Nuosavas kapitalas 2024

Ką veikia Abliva?

The company Abliva AB is a biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases and neurological disorders. The company was founded in 2004 and is headquartered in Stockholm, Sweden. Business Model Abliva AB is an emerging company that focuses on the development of drugs for the treatment of rare diseases and neurological disorders. The company works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. Abliva has a pipeline of promising products at various stages of clinical development. The company also has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Products Abliva specializes in the development of drugs for the treatment of rare diseases. The company has several promising products in its pipeline that are in various stages of clinical development. Additionally, the company has an extensive research and development department that constantly explores and develops new therapeutic options for rare diseases and neurological disorders. One of Abliva's most promising products is a compound called KL1333, which is being developed for the treatment of mitochondrial diseases. KL1333 is a novel drug that aims to improve mitochondrial function and thereby improve the symptoms of mitochondrial diseases. The drug is currently in Phase IIb of development. Another promising product from Abliva is a compound called NV354, which is being developed for the treatment of neuroinflammatory diseases such as multiple sclerosis (MS). NV354 is an innovative compound that inhibits the overactivity of the immune system and reduces inflammation in the nervous system. The drug is currently in the preclinical phase of development. Abliva also has a range of products in development that focus on other neurological disorders such as Parkinson's, Huntington's, and Alzheimer's. Divisions Abliva operates in three main areas: research and development, clinical trials, and commercial development. Research and Development Abliva has an extensive research and development department that constantly explores and develops new therapeutic options for rare diseases and neurological disorders. The company works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. Clinical Trials Abliva conducts clinical trials to test the efficacy and safety of its products. These clinical trials are conducted in close collaboration with specialized research institutions and medical centers to ensure that the results are validated and trustworthy. Commercial Development Abliva aims to bring its products to market to provide patients with access to new therapies that improve their quality of life. The company has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Summary Abliva AB is an emerging biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases and neurological disorders. The company has several promising products in its pipeline that are in various stages of clinical development. Abliva works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. The company also has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Abliva ist eines der beliebtesten Unternehmen auf Eulerpool.com.